Research published on the National Institutes of Health's PubMed platform in May 2024 has provided mechanistic evidence for yerba mate's anti-inflammatory properties, demonstrating that consumption of Ilex paraguariensis extracts can attenuate the severity of experimentally induced colitis through modulation of macrophage polarization — a key process in the innate immune response.
The M1/M2 Macrophage Axis
Macrophages — a class of white blood cells central to immune surveillance — exist along a functional spectrum defined by two primary phenotypes. M1 macrophages drive pro-inflammatory responses, releasing cytokines such as TNF-α and IL-6 that amplify tissue damage in inflammatory conditions. M2 macrophages, conversely, secrete anti-inflammatory mediators including IL-10 and TGF-β, promoting tissue repair and resolution of inflammation. The balance between M1 and M2 polarization is a critical determinant of outcomes in inflammatory bowel disease.
The 2024 study observed that mice receiving yerba mate supplementation exhibited a statistically significant increase in M2 macrophage differentiation within colonic tissue, accompanied by measurable reductions in colitis severity scores. The researchers attributed the immunomodulatory effect primarily to the polyphenolic fraction of yerba mate — particularly chlorogenic acid and its derivatives — which appear to influence transcription factor activation in the macrophage differentiation pathway.
Clinical Implications
While the study was conducted in a murine model and cannot be directly extrapolated to human outcomes, its findings align with a broader body of preclinical literature describing the anti-inflammatory properties of Ilex paraguariensis. A separate systematic review, with searches conducted through September 2025, examined the relationship between yerba mate and rheumatoid arthritis, concluding that yerba mate constituents show preliminary indications of anti-inflammatory and antioxidant effects relevant to autoimmune pathophysiology.
The accumulation of mechanistic evidence has prompted calls within the gastroenterology research community for controlled human trials examining whether regular yerba mate consumption could serve as an adjunctive dietary intervention in inflammatory bowel disease management. The relatively low risk profile of yerba mate as a widely consumed beverage makes it a plausible candidate for translational investigation.